The Globe and Mail reports in its Thursday, March 27, edition that Stifel analyst Justin Keywood has reaffirmed his "hold" recommendation for HLS Therapeutics. The Globe's David Leeder writes that Mr. Keywood gave his share target a 50-cent boost to $4. Analysts on average target the shares at $6.15. Mr. Keywood says in a note: "[HLS Therapeutics] recently issued 2025 guidance, suggesting flat growth and EBITDA to return to near 2023 levels. HLS also recently highlighted a focus on its NCIB for capital allocation and buy backs may continue to push up the stock price with limited liquidity. We conservatively update 2025 estimates with HLS missing its 2024 guidance by a wide margin. Initial 2024 sales guidance was $63.5-million (U.S.) to $66.5-million (U.S.) vs actual, $56.6-million (U.S.). 24' EBITDA guidance also missed by a wide margin. ... HLS valuation may appear cheap on 2025 guidance, risk remains if block selling were to surface with limited liquidity. Product concentration risk also remains, suggesting limited upside. We continue to monitor take-out potential but a relatively large amount of debt, $50-million (U.S.) (net) may limit interest and debt repayment may be a better use of capital vs share buybacks."